Reading between the lines12 Jun 2020 08:29
Allergy
After additional review and evaluation of the use of development resources to deliver the highest potential financial returns, the Board has made the decision to stop on-going development of the allergy product range. Omega will continue to manufacture the 69 CE-Marked allergens developed to date, to meet the ongoing commercial demand from the Company's partner, Immunodiagnostic Systems ("IDS"). The decision to stop development was taken after a careful and thorough analysis of the best use of the Company's capital, people and assets, in the context of changes in underlying assumptions for the allergy business and has resulted in a decision to focus development activities in other areas.c
Those that bailed due to this statement or took a negative view should of realized it was a positive move imo.
I really hope you got your shares back or get a good entry today,it's getting closer and I only intend to top up gla.